摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-decen-1-thiol | 364329-22-6

中文名称
——
中文别名
——
英文名称
9-decen-1-thiol
英文别名
Dec-9-ene-1-thiol
9-decen-1-thiol化学式
CAS
364329-22-6
化学式
C10H20S
mdl
——
分子量
172.335
InChiKey
NNOJUJUSPDAAKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    238.2±19.0 °C(Predicted)
  • 密度:
    0.849±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    11
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    9-decen-1-thiol叔丁基过氧化氢 、 lithium aluminium tetrahydride 、 Mn(dpm)3苯硅烷 作用下, 以 乙醚正己烷异丙醇 为溶剂, 反应 4.0h, 生成 1-癸硫醇
    参考文献:
    名称:
    Simple, Chemoselective Hydrogenation with Thermodynamic Stereocontrol
    摘要:
    Few methods permit the hydrogenation of alkenes to a thermodynamically favored configuration when steric effects dictate the alternative trajectory of hydrogen delivery. Dissolving metal reduction achieves this control, but with extremely low functional group tolerance. Here we demonstrate a catalytic hydrogenation of alkenes that affords the thermodynamic alkane products with remarkably broad functional group compatibility and rapid reaction rates at standard temperature and pressure.
    DOI:
    10.1021/ja412342g
  • 作为产物:
    描述:
    10-iodo-1-decenepotassium carbonatecaesium carbonate 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 反应 35.67h, 生成 9-decen-1-thiol
    参考文献:
    名称:
    Simple, Chemoselective Hydrogenation with Thermodynamic Stereocontrol
    摘要:
    Few methods permit the hydrogenation of alkenes to a thermodynamically favored configuration when steric effects dictate the alternative trajectory of hydrogen delivery. Dissolving metal reduction achieves this control, but with extremely low functional group tolerance. Here we demonstrate a catalytic hydrogenation of alkenes that affords the thermodynamic alkane products with remarkably broad functional group compatibility and rapid reaction rates at standard temperature and pressure.
    DOI:
    10.1021/ja412342g
点击查看最新优质反应信息

文献信息

  • [EN] TETRAZOLINONE COMPOUNDS AND ITS USE<br/>[FR] COMPOSÉS DE TÉTRAZOLINONE ET LEUR UTILISATION
    申请人:SUMITOMO CHEMICAL CO
    公开号:WO2013162077A1
    公开(公告)日:2013-10-31
    The present invention provides a compound having an excellent efficacy for controlling pests. A tetrazolinone compound of a formula (1): [wherein, R1 represents an C6-C16 aryl group, an C1-C12 alkyl group, a C3-C12 cycloalkyl group or an adamantyl group, etc., which each optionally be substituted; R2 represents a hydrogen atom, an C1-C12 alkyl group, or a halogen atom, etc.; R4 and R5 represent independently of each other a hydrogen atom or an C1-C3 alkyl group, etc.; R6, R7, R8 and R9 represent independently of each other a hydrogen atom, a halogen atom, an C1-C12 alkyl group, a C1-C12 haloalkyl group, an C2-C12 alkenyl group, a C3-C12 cycloalkyl group, an C1-C12 alkoxy group or a C1-C12 haloalkoxy group, etc.; X and Y represent independently of each other a sulfur atom or an oxygen atom; Q represents an oxygen atom or a sulfur atom; and R10 represents an C1-C6 alkyl group, etc.] shows an excellent controlling efficacy on pests.
    本发明提供了一种具有优异杀虫效果的化合物。式(1)中的四氮杂酮化合物:[其中,R1代表一个C6-C16芳基,一个C1-C12烷基,一个C3-C12环烷基或一个金刚烷基等,每个都可以选择性地被取代;R2代表一个氢原子,一个C1-C12烷基或一个卤素原子等;R4和R5分别独立地代表一个氢原子或一个C1-C3烷基等;R6、R7、R8和R9分别独立地代表一个氢原子,一个卤素原子,一个C1-C12烷基,一个C1-C12卤代烷基,一个C2-C12烯基,一个C3-C12环烷基,一个C1-C12烷氧基或一个C1-C12卤代烷氧基等;X和Y分别独立地代表一个硫原子或一个氧原子;Q代表一个氧原子或一个硫原子;R10代表一个C1-C6烷基等]对害虫有极佳的控制效果。
  • Amide derivatives
    申请人:Muto Susumu
    公开号:US20050215645A1
    公开(公告)日:2005-09-29
    A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein one of R 1 and R 2 represents hydrogen atom and the other represents the formula —X-A wherein A represents hydrogen atom or an acyl group, X represents oxgen atom or NH; one of R 3 and R 4 represents hydrogen atom and the other represents the following formula: wherein Y represents a sulfonyl group or a carbonyl group, R 5 represents a cyclic group, Z represents a single bond or a C 1 to C 4 alkylene group, R 6 represents hydrogen atom or a C 1 to C 6 alkyl group.
    一种用于增强基于DNA损伤作用的癌症治疗效果的药物,其活性成分为以下一般式(I)或其盐表示的化合物:其中R1和R2中的一个代表氢原子,另一个代表式—X-A,其中A代表氢原子或酰基,X代表氧原子或NH;R3和R4中的一个代表氢原子,另一个代表以下式:其中Y代表磺酰基或羰基,R5代表环状基团,Z代表单键或C1到C4烷基烷基,R6代表氢原子或C1到C6烷基基团。
  • INFLAMMATORY CYTOKINE RELEASE INHIBITOR
    申请人:MUTO Susumu
    公开号:US20090192122A2
    公开(公告)日:2009-07-30
    A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.
    一种具有抑制NF-κB激活活性的药物,其包括以下通式(I)所表示的化合物或其药理学上可接受的盐作为活性成分:其中X代表连接基,A代表氢原子或乙酰基,E代表芳基或杂芳基,环X代表芳烃或杂芳烃。
  • Nf-kb activation inhibitors
    申请人:Muto Susumu
    公开号:US20060089395A1
    公开(公告)日:2006-04-27
    A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.
    一种药物具有抑制NF-κB活化作用,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中A代表氢原子或乙酰基,E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基,其可以被取代,但在所述杂环芳基是圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基,圆圈(2)}未取代的噻唑-2-基团,或者圆圈(3)}未取代的苯并噻唑-2-基团时,不包括该化合物,环Z代表一个芳香烃,除了由公式—O-A所表示的基团外,它也可以有一个或多个取代基,其中A具有与上述定义相同的含义,公式—CONH-E所表示的基团E具有与上述定义相同的含义。
  • O-substituted hydroxyaryl derivatives
    申请人:Muto Susumu
    公开号:US20060094718A1
    公开(公告)日:2006-05-04
    A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C 1 to C 6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种药物具有抑制NF-κB激活活性,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物作为活性成分,其中X表示主链中原子数为2至5的连接基(该连接基可以被取代),A表示可以被取代的酰基(不包括未取代的乙酰基和未取代的丙烯酰基)或者可以被取代的C1到C6烷基,或者A可以与连接基X结合形成可以被取代的环状结构,E表示可以被取代的芳基或者可以被取代的杂环基,环Z表示可以具有一个或多个取代基的芳基(除了由式—O-A所表示的基团外,A具有与上述定义相同的含义,由式—X-E所表示的基团,X和E具有与上述定义相同的含义)或者可以具有一个或多个取代基的杂环基(除了由式—O-A所表示的基团外,A具有与上述定义相同的含义,由式—X-E所表示的基团,X和E具有与上述定义相同的含义)。
查看更多